Some patients with positive chest CT findings may present with negative results of real time reverse-transcription–polymerase chain- reaction (RT-PCR) for 2019 novel coronavirus (2019-nCoV). In thi...

Objective: To investigate the value of Computed Tomography (CT) radiomics derived from different peritumoral volumes of interest (VOIs) in predicting epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma patients. Materials and methods: A retrospective cohort of 779 patients who had pathologically confirmed lung adenocarcinoma were enrolled. 640 patients were randomly divided into a training set, a validation set, and an internal testing set (3:1:1), and the remaining 139 patients were defined as an external testing set. The intratumoral VOI (VOI_I) was manually delineated on the thin-slice CT images, and seven peritumoral VOIs (VOI_P) were automatically generated with 1, 2, 3, 4, 5, 10, and 15 mm expansion along the VOI_I. 1454 radiomic features were extracted from each VOI. The t-test, the least absolute shrinkage and selection operator (LASSO), and the minimum redundancy maximum relevance (mRMR) algorithm were used for feature selection, followed by the construction of radiomics models (VOI_I model, VOI_P model and combined model). The performance of the models were evaluated by the area under the curve (AUC). Results: 399 patients were classified as EGFR mutant (EGFR+), while 380 were wild-type (EGFR−). In the training and validation sets, internal and external testing sets, VOI4 (intratumoral and peritumoral 4 mm) model achieved the best predictive performance, with AUCs of 0.877, 0.727, and 0.701, respectively, outperforming the VOI_I model (AUCs of 0.728, 0.698, and 0.653, respectively). Conclusions: Radiomics extracted from peritumoral region can add extra value in predicting EGFR mutation status of lung adenocarcinoma patients, with the optimal peritumoral range of 4 mm.

Background: The focus of neuro‐oncology research has changed from histopathologic grading to molecular characteristics, and medical imaging routinely follows this change.Purpose: To compare the diagnostic performance of amide proton transfer (APT) and four diffusion models in gliomas grading and isocitrate dehydrogenase (IDH) genotype.Study Type: Prospective.Population: A total of 62 participants (37 males, 25 females; mean age, 52 ± 13 years) whose IDH genotypes were mutant in 6 of 14 grade II gliomas, 8 of 20 of grade III gliomas, and 4 of 28 grade IV gliomas.Field Strength/Sequence: APT imaging using sampling perfection with application optimized contrasts by using different flip angle evolutions (SPACE) and DWI with q‐space Cartesian grid sampling were acquired at 3 T.Assessment: The ability of diffusion kurtosis imaging, diffusion kurtosis imaging, neurite orientation dispersion and density imaging (NODDI), mean apparent propagator (MAP), and APT imaging for glioma grade and IDH status were assessed, with histopathological grade and genetic testing used as a reference standard. Regions of interest (ROIs) were drawn by two neuroradiologists after consensus.Statistical Tests: T‐test and Mann–Whitney U test; one‐way analysis of variance (ANOVA); receiver operating curve (ROC) and area under the curve (AUC); DeLong test. P value < 0.05 was considered statistically significant.Results: Compared with IDH‐mutant gliomas, IDH‐wildtype gliomas showed a significantly higher mean, 5th‐percentile (APT₅), and 95th‐percentile from APTw, the 95th‐percentile value of axial, mean, and radial diffusivity from DKI, and 95th‐percentile value of isotropic volume fraction from NODDI, and no significantly different parameters from DTI and MAP (P = 0.075–0.998). The combined APT model showed a significantly wider area under the curve (AUC 0.870) for IDH status, when compared with DKI and NODDI. APT₅ was significantly different between two of the three groups (glioma II vs. glioma III vs. glioma IV: 1.35 ± 0.75 vs. 2.09 ± 0.93 vs. 2.71 ± 0.81).Data conclusion: APT has higher diagnostic accuracy than DTI, DKI, MAP, and NODDI in glioma IDH genotype. APT₅ can effectively identify both tumor grading and IDH genotyping, making it a promising biomarker for glioma classification.Evidence Level: 1Technical Efficacy: Stage 2

Early and accurate severity assessment of Coronavirus disease 2019 (COVID-19) based on computed tomography (CT) images offers a great help to the estimation of intensive care unit event and the clinical decision of treatment planning. To augment the labeled data and improve the generalization ability of the classification model, it is necessary to aggregate data from multiple sites. This task faces several challenges including class imbalance between mild and severe infections, domain distribution discrepancy between sites, and presence of heterogeneous features. In this paper, we propose a novel domain adaptation (DA) method with two components to address these problems. The first component is a stochastic class-balanced boosting sampling strategy that overcomes the imbalanced learning problem and improves the classification performance on poorly-predicted classes. The second component is a representation learning that guarantees three properties: 1) domain-transferability by prototype triplet loss, 2) discriminant by conditional maximum mean discrepancy loss, and 3) completeness by multi-view reconstruction loss. Particularly, we propose a domain translator and align the heterogeneous data to the estimated class prototypes (i.e., class centers) in a hyper-sphere manifold. Experiments on cross-site severity assessment of COVID-19 from CT images show that the proposed method can effectively tackle the imbalanced learning problem and outperform recent DA approaches.

Achieving clinical level performance and widespread deployment for generating radiology impressions encounters a giant challenge for conventional artificial intelligence models tailored to specific diseases and organs. Concurrent with the increasing accessibility of radiology reports and advancements in modern general AI techniques, the emergence and potential of deployable radiology AI exploration have been bolstered. Here, we present ChatRadio-Valuer, the first general radiology diagnosis large language model for localized deployment within hospitals and being close to clinical use for multi-institution and multi-system diseases. ChatRadio-Valuer achieved 15 state-of-the-art results across five human systems and six institutions in clinical-level events (n = 332,673) through rigorous and full-spectrum assessment, including engineering metrics, clinical validation, and efficiency evaluation. Notably, it exceeded OpenAI's GPT-3.5 and GPT-4 models, achieving superior performance in comprehensive disease diagnosis compared to the average level of radiology experts. Besides, ChatRadio-Valuer supports zero-shot transfer learning, greatly boosting its effectiveness as a radiology assistant, while ensuring adherence to privacy standards and being readily utilized for large-scale patient populations. Our expeditions suggest the development of localized LLMs would become an imperative avenue in hospital applications.